the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

NCT04978753 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
54
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Li-kun Chen